Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 555 participants.

Also called NCT01169818

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 555 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01169818
Other papers using this trial's data
  • Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015-02 DOI, PubMed 25297660

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, India, Japan, Pakistan, Philippines, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01169818. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus
Acronym
ATLAS
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Glargine
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01169818
Content hash
6d3f21de17747a628fa159db7053b616fb63c21f0377e169d6c50af31f1ce838